SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
CTIX - Cellceutix Corporation
An SI Board Since May 2008
Posts SubjectMarks Bans Symbol
106 17 0 CTIX
Emcee:  Savant Type:  Moderated
Introduction Market Data Compact
Cellceutix Corporation (OTCBB CTIX): At Cellceutix, we have an exciting pipeline. We have the expertise of a large pharmaceutical company, but we're also focused, nimble and willing to supplement our own creative energies with ideas from the outside. We're focused on our lead candidate, Kevetrin, which we plan to develop for head and neck cancer. And we're focused on developing high quality data and patents to support Kevetrin. We're also open to new ideas from outside as well as inside. As a matter of fact, our pipeline already includes compounds licensed from the outside to supplement those invented by one of our co-founders, Dr. Krishna Menon. We're willing to partner with anyone who will help us meet our goals. When you put all this together, it means we at Cellceutix have a very exciting opportunity to create real value for our shareholders, as well as for our ultimate customers, the patients.
Website: cellceutix.com OTCBB Profile: otcbb.com
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
106 Cellceutix Reports on Q2 Fiscal 2017, Prepares for Important Clinical MilestoneSavant-2/16/2017
105Cellceutix Strongly Denounces Criminal Enterprise Mako Research, Who Published FSavant11/17/2017
104Cellceutix Wishes Shareholders Happy Holidays, Prepares for 2017 Focused on PartSavant-12/22/2016
103Cellceutix Reports 24 Core Phase 2b Clinical Trial Sites for Oral Prurisol TreatSavant-12/19/2016
102Cellceutix Reports Advances in Developing Kevetrin as an Oral Ovarian Cancer TreSavant-12/15/2016
101Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Savant112/7/2016
100Cellceutix Novel Anti-Inflammatory Phase 2 Drug Candidate Brilacidin Builds MomeSavant-10/26/2016
99Cellceutix Phase 2 Trial Initial Data Shows Potential of Brilacidin as a Novel ASavant-10/10/2016
98Cellceutix Prepares Phase 2a Ovarian Cancer Trial of Kevetrin, a Novel p53-ModulSavant-8/3/2016
97Cellceutix Expedites Phase 2 Trial of Brilacidin-OM For Oral Mucositis Jul 21, Savant-7/21/2016
96Cellceutix Receives Update on First Patient Enrolled in Phase 2 Proof-of-ConceptSavant-7/20/2016
95Cellceutix to Initiate Phase 2b Trial of Prurisol for Chronic Plaque Psoriasis Savant-7/12/2016
94Cellceutix Starts Phase 2 Trial of Brilacidin as a Novel Therapy for Ulcerative Savant-6/15/2016
93CTIX announced lock on Kevetrin for cancer phase 1 trials today May 25 & 26Savant-6/6/2016
92Interesting article on Seeking Alpha - I am long as a spec but would be interestThehammer-4/2/2016
91Cellceutix Successfully Completes In Vitro Study in Support of Planned PhaseSavant-3/31/2016
90Cellceutix Receives Preliminary Approval for Clinical Trial of Brilacidin foSavant-3/30/2016
89Cellceutix Concludes Last Patient Visit in Phase 2 FDA Trial of Oral Dosed PSavant-3/17/2016
88Cellceutix Completes Dosing in Phase 2 Trial of Prurisol for Chronic Psoriasis, Savant-3/1/2016
87Assay Results From Cellceutix Phase 1 Clinical Trial of Kevetrin for CancerSavant-2/26/2016
86Cellceutix Submits Special Protocol Assessment Request to FDA for Phase 3 ClSavant-2/26/2016
85Cellceutix Completes Clinical Trial of Kevetrin for Advanced Solid Tumors BSavant-2/16/2016
84Cellceutix Files Motion to Dismiss Complaint Filed by The Rosen Law Firm BESavant-2/12/2016
83Cellceutix Met With FDA for Phase 2 Clinical Trial of Kevetrin for Ovarian Savant-2/10/2016
82Cellceutix to Submit Special Protocol Assessment Request to FDA for Phase 3 Savant-2/9/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News